Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

被引：1
|
作者：
Khountham, Soun [1 ]
Shindiapina, Polina [1 ]
Mo, Xiaokui [2 ]
Lachowiez, Curtis [3 ]
Wiczer, Tracy [4 ]
Mousa, Luay [1 ]
Rogers, Kerry A. [1 ]
Andritsos, Leslie A. [1 ]
Woyach, Jennifer A. [1 ]
Byrd, John C. [1 ]
Spurgeon, Stephen E. [3 ]
Awan, Farrukh T. [5 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA
[3] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Dept Pharm, Columbus, OH 43210 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Div Hematol & Med Oncol, Dallas, TX 75390 USA
来源：
LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 03期
关键词：
ATRIAL-FIBRILLATION; OUTCOMES; THERAPY;
D O I：
10.1080/10428194.2020.1838508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：716 / 721
页数：6
相关论文
共 50 条
  • [31] Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
    Hampel, Paul J.
    Call, Timothy G.
    Rabe, Kari G.
    Ding, Wei
    Muchtar, Eli
    Kenderian, Saad S.
    Wang, Yucai
    Leis, Jose F.
    Witzig, Thomas E.
    Koehler, Amber B.
    Fonder, Amie L.
    Schwager, Susan M.
    Van Dyke, Daniel L.
    Braggio, Esteban
    Slager, Susan L.
    Kay, Neil E.
    Parikh, Sameer A.
    ONCOLOGIST, 2020, 25 (11): : 974 - 980
  • [32] Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
    Jain, Preetesh
    Thompson, Philip A.
    Keating, Michael
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    Kantarjian, Hagop
    Burger, Jan A.
    O'Brien, Susan
    Wierda, William G.
    CANCER, 2017, 123 (12) : 2268 - 2273
  • [33] Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
    Ryan, Christine E.
    Sahaf, Bita
    Logan, Aaron C.
    O'Brien, Susan
    Byrd, John C.
    Hillmen, Peter
    Brown, Jennifer R.
    Dyer, Martin J. S.
    Mato, Anthony R.
    Keating, Michael J.
    Jaglowski, Samantha
    Clow, Fong
    Rezvani, Andrew R.
    Styles, Lori
    Coutre, Steven E.
    Miklos, David B.
    BLOOD, 2016, 128 (25) : 2899 - 2908
  • [34] Ibrutinib and its use in the treatment o chronic lymphocytic leukemia
    Frustaci, Anna Maria
    Tedeschi, Alessandra
    Deodato, Marina
    Mazzucchelli, Maddalena
    Cairoli, Roberto
    Montillo, Marco
    FUTURE ONCOLOGY, 2018, 14 (08) : 681 - 697
  • [35] Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
    Kidoguchi, Keisuke
    Kubota, Yasushi
    Nishimura, Yuki
    Kizuka-Sano, Haruna
    Kimura, Shinya
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 83 - 85
  • [36] Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
    Gaye, E.
    Le Bot, A.
    Talarmin, J. P.
    Le Calloch, R.
    Belaz, S.
    Dupont, M.
    Tattevin, P.
    MEDECINE ET MALADIES INFECTIEUSES, 2018, 48 (04): : 294 - 297
  • [37] Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Mauro, Francesca Romana
    Giannarelli, Diana
    Visentin, Andrea
    Reda, Gianluigi
    Sportoletti, Paolo
    Frustaci, Anna Maria
    Chiarenza, Annalisa
    Ciolli, Stefania
    Vitale, Candida
    Laurenti, Luca
    De Paoli, Lorenzo
    Murru, Roberta
    Gentile, Massimo
    Rigolin, Gian Matteo
    Levato, Luciano
    Giordano, Annamaria
    Del Poeta, Giovanni
    Stelitano, Caterina
    Ielo, Claudia
    Noto, Alessandro
    Guarente, Valerio
    Molica, Stefano
    Coscia, Marta
    Tedeschi, Alessandra
    Gaidano, Gianluca
    Cuneo, Antonio
    Foa, Robin
    Martelli, Maurizio
    Girmenia, Corrado
    Gentile, Giuseppe
    Trentin, Livio
    CANCERS, 2021, 13 (13)
  • [38] Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG)
    Iskierka-Jazdzewska, Elzbieta
    Pula, Bartosz
    Szeremet, Agnieszka
    Hus, Marek
    Golos, Aleksandra
    Holojda, Jadwiga
    Piszczek, Weronika
    Steckiewicz, Pawel
    Wojciechowska, Malgorzata
    Zaucha, Jan Maciej
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (08): : 1051 - 1057
  • [39] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [40] Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
    Hampel, Paul J.
    Ding, Wei
    Call, Timothy G.
    Rabe, Kari G.
    Kenderian, Saad S.
    Witzig, Thomas E.
    Muchtar, Eli
    Leis, Jose F.
    Chanan-Khan, Asher A.
    Koehler, Amber B.
    Fonder, Amie L.
    Schwager, Susan M.
    Slager, Susan L.
    Shanafelt, Tait D.
    Kay, Neil E.
    Parikh, Sameer A.
    LEUKEMIA & LYMPHOMA, 2019, 60 (11) : 2712 - 2719
12345